Abstract 61P
Background
It was reported that programmed death-ligand 1 (PD-L1) high expression may result in worse outcomes of third-generation EGFR-TKIs compared with PD-L1 low expression or negative in EGFR-mutant advanced NSLCLC. This study aims to investigate the efficacy of first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant advanced NSCLC with high PD-L1 expression.
Methods
A retrospective review of medical records was performed to analyze EGFR-mutant advanced NSCLC patients. These patients were admitted to Guangdong Provincial People’s Hospital between January 1, 2022 and September 25, 2024. All patients received first-line osimertinib or osimertinib plus pemetrexed/carboplatin treatment. Median progression-free survival (mPFS) and objective response rate (ORR) were assessed. In vivo drug response of PDOs (Patient derived organoid) were performed.
Results
Totally 126 eligible patients were enrolled in the study, of which 15.1% (n=19) were in high PD-L1 expression (tumor proportion score, TPS≥50%) group, 31.0% (n=39) in low PD-L1 expression (1%≤TPS
Conclusions
Osimertinib plus pemetrexed/carboplatin treatment may lead to better short-term response, but long-term efficacy remains to be further assessed.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.